Controlling the Receptor for Advanced Glycation End-products to Conquer Diabetic Vascular Complications

Overview

Journal J Diabetes Investig

Specialty Endocrinology

Date 2014 May 21

PMID 24843553

Citations 12

Authors

Yasuhiko Yamamoto

Hiroshi Yamamoto

Affiliations

Soon will be listed here.

Abstract

Diabetic vascular complications, such as cardiovascular disease, stroke and microangiopathy, lead to high rates of morbidity and mortality in patients with long-term diabetes. Extensive intracellular and extracellular formation of advanced glycation end-products (AGE) is considered a causative factor in vascular injuries in diabetes. Receptor-dependent mechanisms are involved in AGE-induced cellular dysfunction and tissue damage. The receptor for AGE (RAGE), originally an AGE-binding receptor, is now recognized as a member of pattern-recognition receptors and a pro-inflammatory molecular device that mediates danger signals to the body. Previous animal studies have shown RAGE dependent of diabetic vascular injuries. Prophylactic and therapeutic strategies focusing on RAGE and its ligand axis will be of great importance in conquering diabetic vascular complications. (J Diabetes Invest, doi: 10.1111/j.2040-1124.2011.00191.x, 2012).

Citing Articles

The Decrease in Serum sRAGE Levels Upon Smoking is Associated with Activated Neutrophils.

Wiersma V, Hoonhorst S, Ten Hacken N, van den Berge M, Slebos D, Pouwels S Lung. 2022; 200(6):687-690.

PMID: 36282357 PMC: 9675764. DOI: 10.1007/s00408-022-00585-4.

Inhibitory Effects of Extract on Receptor for Advanced Glycation End-Products-Dependent Inflammation and Diabetes-Induced Dysregulation of Vasodilation.

Hayashi K, Sato K, Ochi S, Kawano S, Munesue S, Harashima A Int J Mol Sci. 2022; 23(10).

PMID: 35628567 PMC: 9147798. DOI: 10.3390/ijms23105757.

Dual Nature of RAGE in Host Reaction and Nurturing the Mother-Infant Bond.

Oshima Y, Harashima A, Munesue S, Kimura K, Leerach N, Goto H Int J Mol Sci. 2022; 23(4).

PMID: 35216202 PMC: 8880422. DOI: 10.3390/ijms23042086.

Glycation reaction and the role of the receptor for advanced glycation end-products in immunity and social behavior.

Leerach N, Harashima A, Munesue S, Kimura K, Oshima Y, Goto H Glycoconj J. 2020; 38(3):303-310.

PMID: 33108607 DOI: 10.1007/s10719-020-09956-6.

Effect of Berberine on Glycation, Aldose Reductase Activity, and Oxidative Stress in the Lenses of Streptozotocin-Induced Diabetic Rats In Vivo-A Preliminary Study.

Zych M, Wojnar W, Kielanowska M, Folwarczna J, Kaczmarczyk-Sedlak I Int J Mol Sci. 2020; 21(12).

PMID: 32560082 PMC: 7349706. DOI: 10.3390/ijms21124278.

References

Win M, Yamamoto Y, Munesue S, Saito H, Han D, Motoyoshi S . Regulation of RAGE for attenuating progression of diabetic vascular complications. Exp Diabetes Res. 2011; 2012:894605. PMC: 3205669. DOI: 10.1155/2012/894605. View

Li J, Qu X, Yao J, Caruana G, Ricardo S, Yamamoto Y . Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy. Diabetes. 2010; 59(10):2612-24. PMC: 3279546. DOI: 10.2337/db09-1631. View

Pongrac Barlovic D, Soro-Paavonen A, Jandeleit-Dahm K . RAGE biology, atherosclerosis and diabetes. Clin Sci (Lond). 2011; 121(2):43-55. DOI: 10.1042/CS20100501. View

Torreggiani M, Liu H, Wu J, Zheng F, Cai W, Striker G . Advanced glycation end product receptor-1 transgenic mice are resistant to inflammation, oxidative stress, and post-injury intimal hyperplasia. Am J Pathol. 2009; 175(4):1722-32. PMC: 2751567. DOI: 10.2353/ajpath.2009.090138. View

Joshi D, Gupta R, Dubey A, Shiwalkar A, Pathak P, Gupta R . TRC4186, a novel AGE-breaker, improves diabetic cardiomyopathy and nephropathy in Ob-ZSF1 model of type 2 diabetes. J Cardiovasc Pharmacol. 2009; 54(1):72-81. DOI: 10.1097/FJC.0b013e3181ac3a34. View

Wang Y, Wang H, Piper M, McMaken S, Mo X, Opalek J . sRAGE induces human monocyte survival and differentiation. J Immunol. 2010; 185(3):1822-35. PMC: 3671884. DOI: 10.4049/jimmunol.0903398. View

Huttunen H, Fages C, Rauvala H . Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem. 1999; 274(28):19919-24. DOI: 10.1074/jbc.274.28.19919. View

Schwedler S, Verbeke P, Bakala H, Weiss M, Vilar J, Depreux P . N-phenacylthiazolium bromide decreases renal and increases urinary advanced glycation end products excretion without ameliorating diabetic nephropathy in C57BL/6 mice. Diabetes Obes Metab. 2001; 3(4):230-9. DOI: 10.1046/j.1463-1326.2001.00096.x. View

Zhu W, Sano H, Nagai R, Fukuhara K, Miyazaki A, Horiuchi S . The role of galectin-3 in endocytosis of advanced glycation end products and modified low density lipoproteins. Biochem Biophys Res Commun. 2001; 280(4):1183-8. DOI: 10.1006/bbrc.2001.4256. View

10.

Danaei G, Finucane M, Lu Y, Singh G, Cowan M, Paciorek C . National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet. 2011; 378(9785):31-40. DOI: 10.1016/S0140-6736(11)60679-X. View

11.

Cheng G, Wang L, Long L, Liu H, Cui H, Qu W . Beneficial effects of C36, a novel breaker of advanced glycation endproducts cross-links, on the cardiovascular system of diabetic rats. Br J Pharmacol. 2007; 152(8):1196-206. PMC: 2189992. DOI: 10.1038/sj.bjp.0707533. View

12.

Vlassara H, Li Y, Imani F, Wojciechowicz D, Yang Z, Liu F . Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med. 1995; 1(6):634-46. PMC: 2229987. View

13.

Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M . Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest. 2001; 108(2):261-8. PMC: 203021. DOI: 10.1172/JCI11771. View

14.

Sell D, Monnier V . Structure elucidation of a senescence cross-link from human extracellular matrix. Implication of pentoses in the aging process. J Biol Chem. 1989; 264(36):21597-602. View

15.

Cheng C, Tsuneyama K, Kominami R, Shinohara H, Sakurai S, Yonekura H . Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs. Mod Pathol. 2005; 18(10):1385-96. DOI: 10.1038/modpathol.3800450. View

16.

Kaji Y, Usui T, Ishida S, Yamashiro K, Moore T, Moore J . Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Invest Ophthalmol Vis Sci. 2007; 48(2):858-65. DOI: 10.1167/iovs.06-0495. View

17.

Miyata T, Wada Y, Cai Z, Iida Y, Horie K, Yasuda Y . Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int. 1997; 51(4):1170-81. DOI: 10.1038/ki.1997.160. View

18.

Sakurai S, Yamamoto Y, Tamei H, Matsuki H, Obata K, Hui L . Development of an ELISA for esRAGE and its application to type 1 diabetic patients. Diabetes Res Clin Pract. 2006; 73(2):158-65. DOI: 10.1016/j.diabres.2005.12.013. View

19.

Yao D, Taguchi T, Matsumura T, Pestell R, Edelstein D, Giardino I . High glucose increases angiopoietin-2 transcription in microvascular endothelial cells through methylglyoxal modification of mSin3A. J Biol Chem. 2007; 282(42):31038-45. DOI: 10.1074/jbc.M704703200. View

20.

Wendt T, Tanji N, Guo J, Kislinger T, Qu W, Lu Y . RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol. 2003; 162(4):1123-37. PMC: 1851245. DOI: 10.1016/S0002-9440(10)63909-0. View